BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22338470)

  • 1. [Allergic complications of L-asparaginase therapy in children with acute lymphoblastic leukaemia].
    Konstantinidis N; Kolarović J; Kaćanski N; Vijatov-Djurić G; Konstantinidis G
    Srp Arh Celok Lek; 2011; 139(11-12):749-52. PubMed ID: 22338470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
    Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
    Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
    Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
    Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
    Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
    Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
    Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
    Billett AL; Carls A; Gelber RD; Sallan SE
    Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
    Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
    Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
    Ovalle B P; Azócar M M; Nicklas D C; Villarroel C M; Morales V J
    Andes Pediatr; 2021 Apr; 92(2):182-192. PubMed ID: 34106156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
    Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
    Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
    Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
    J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
    Sikorska-Fic B; Makowska K; Rokicka-Milewska R
    Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
    Ebeid EN; Kamel MM; Ali BA
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adverse reactions to L-asparaginase in children with acute lymphatic leukemia].
    Kyonen L M; Folatre B I; Zolezzi R P; Badilla M V; Marín H F
    Rev Med Chil; 2006 Dec; 134(12):1530-4. PubMed ID: 17277869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
    Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
    Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.